Fulltext

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)

Pestalozzi, B. C. ; Zahrieh, D. ; Price, K. N. ; Holmberg, S. B. ; Lindtner, J. ; Collins, J. ; Crivellari, D. ; Fey, M. F. ; Murray, E. ; Pagani, O. ; Simoncini, E. ; Castiglione-Gertsch, M. ; Gelber, R. D. ; Coates, A. S. ; Goldhirsch, A.

In: Annals of Oncology, 2006, vol. 17, no. 6, p. 935-944

Ajouter à la liste personnelle
    Titre
    • Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
    Auteur
    • Pestalozzi, B. C.. Department of Oncology, University Hospital, Zürich, Switzerland and the Swiss Group for Clinical Cancer Research (SAKK)
    • Zahrieh, D.. IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA
    • Price, K. N.. Frontier Science and Technology Research Foundation, Boston, MA, USA
    • Holmberg, S. B.. Department of Surgery, SU/Moelndal's Hospital, Moelndal, Sweden
    • Lindtner, J.. Department of Surgery, Institute of Oncology, Ljubljana, Slovenia
    • Collins, J.. Department of Surgery, Royal Melbourne Hospital, Australian New Zealand Breast Cancer Trials Group, Melbourne, Australia
    • Crivellari, D.. Centro di Riferimento Oncologico, Aviano, Italy
    • Fey, M. F.. Department of Medical Oncology, Inselspital, Bern, Switzerland and the Swiss Group for Clinical Cancer Research (SAKK)
    • Murray, E.. Groote Schuur Hospital and University of Cape Town, South Africa
    • Pagani, O.. Oncology Institute of Southern Switzerland, Lugano, Switzerland and the Swiss Group for Clinical Cancer Research (SAKK)
    • Simoncini, E.. Oncologia Medica-Spedali Civili, Brescia, Italy
    • Castiglione-Gertsch, M.. IBCSG Coordinating Center, and Institute of Medical Oncology, Inselspital, Bern, Switzerland
    • Gelber, R. D.. IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA
    • Coates, A. S.. The Cancer Council Australia, Australian New Zealand Breast Cancer Trials Group and School of Public Health, University of Sydney, Australia
    • Goldhirsch, A.. Oncology Institute of Southern Switzerland, Lugano, Switzerland and the Swiss Group for Clinical Cancer Research (SAKK)
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2006, vol. 17, no. 6, p. 935-944. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:299792
    Summary
    Background: We sought to determine whether a high-risk group could be defined among patients with operable breast cancer in whom a search of occult central nervous system (CNS) metastases was justified. Patients and methods: We evaluated data from 9524 women with early breast cancer (42% node-negative) who were randomized in International Breast Cancer Study Group clinical trials between 1978 and 1999, and treated without anthracyclines, taxanes, or trastuzumab. We identified patients whose site of first event was CNS and those who had a CNS event at any time. Results: Median follow-up was 13 years. The 10-year incidence (10-yr) of CNS relapse was 5.2% (1.3% as first recurrence). Factors predictive of CNS as first recurrence included: node-positive disease (10-yr = 2.2% for > 3 N+), estrogen receptor-negative (2.3%), tumor size > 2 cm (1.7%), tumor grade 3 (2.0%), < 35 years old (2.2%), HER2-positive (2.7%), and estrogen receptor-negative and node-positive (2.6%). The risk of subsequent CNS recurrence was elevated in patients experiencing lung metastases (10-yr = 16.4%). Conclusion: Based on this large cohort we were able to define risk factors for CNS metastases, but could not define a group at sufficient risk to justify routine screening for occult CNS metastases